Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mix Vaccine + Standard Therapy in Prostate Carcinoma
NCT02338700Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Jan 2015
- Primary completion
- Aug 2015
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in prostate carcinoma (2 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 at 2 years. Started Jan 2015; status: completed.
02
Conditions
prostate carcinoma
Beyond the preview
Go deeper on NCT02338700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02338700.